by Christine M. Kukka
Coinfected patients treated with new, successful
hepatitis C antivirals drugs face a potentially life-threatening
reactivation of their hepatitis B infection—even if their hepatitis B is
resolved or inactive.
Up to 30
percent of people infected with hepatitis C are also infected with
hepatitis B. In these coinfected patients, hepatitis C becomes the
“dominant” virus in the liver and suppresses hepatitis B to barely
detectable levels. When the new antiviral drugs, including sofosbuvir
(Solvadi) are used, hepatitis B can resurge as hepatitis C retreats.
In
the past, hepatitis C treatment used the antiviral ribavirin and
pegylated interferon. While ribavirin targeted only hepatitis C, the
interferon treatment helped the immune system fight both hepatitis C and
B.
Today’s fast-acting hepatitis C
treatment contains only antivirals that target only hepatitis C. Once
hepatitis C is eradicated, doctors are finding a few cases where
coinfected patients quickly experience a dangerous reactivation of their
hepatitis B infection, even if they had “inactive” or resolved
hepatitis B.
This discovery is significant, according to a report published in the current issue of the journal of Clinical Infectious Diseases,
because current hepatitis C treatment guidelines, “do not offer
specific guidance on treatment and monitoring of patients coinfected
with hepatitis B.”
As a result,
doctors don’t know they should be looking for hepatitis B reactivation
in patients treated with sofosbuvir and simeprevir. However, coinfected
patients may be among the first treated with the new drugs by doctors
and Veterans Administration clinics because coinfections can produce
more serious liver damage that requires treatment.
The
journal article reports on two coinfected patients treated with
sofosbuvir and simeprevir. One patient achieved undetectable hepatitis C
viral load within four weeks, but seven weeks after starting treatment
he developed jaundice and abdominal pain. Doctors at Emory University
School of Medicine discovered he had a sudden reactivation of hepatitis
B. His hepatitis B viral load, which had been very low before treatment,
jumped into the millions and blood tests revealed severe liver damage.
Doctors
stopped treatment and started him on the hepatitis B antiviral
tenofovir (Viread), which quickly controlled the hepatitis B flare.
After 28 weeks, the patient’s hepatitis B remained under control and he
remained cured of hepatitis C.
In the
second reported case, a patient who had cleared a hepatitis B infection
and had hepatitis B surface antibodies, was treated with the same
antivirals. This time, doctors monitored his hepatitis B and C viral
load every two weeks. As expected, the hepatitis C virus disappeared
while the hepatitis B viral load rapidly rose. This time, doctors added
tenofovir to the ongoing treatment and 12 weeks later the patient tested
undetectable for both viruses.
Researchers
urged doctors to screen hepatitis C patients for signs of past or
current hepatitis B infections before starting the new treatment, and to
monitor hepatitis B viral load during treatment.
Labels: Coinfection, hepatitis C treatment, reactivation of HBV by sofosbuvir and simeprevir, treatment